TELA Bio, Inc.
NasdaqGM:TELA 株式レポート
TELA Bio マネジメント TELA Bioの CEO はAntony Koblishで、 Apr2012年に任命され、 の在任期間は 12.58年です。 の年間総報酬は$ 2.37Mで、 25.2%給与と74.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.22%を直接所有しており、その価値は$ 888.47K 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と5年です。
主要情報 CEO給与比率 25.2% CEO在任期間 12.6yrs CEOの所有権 1.2% 経営陣の平均在職期間 3.2yrs 取締役会の平均在任期間 5yrs
経営陣の近況
すべての更新を表示
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely Nov 09 TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $40.04942 million. Oct 24
TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $40.04942 million.
TELA Bio, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 18
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33% Aug 19
TELA Bio, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 23 TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell Small Cap Completeness Index
Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet? Jul 03
TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors Jun 06
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now May 29
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward May 23
TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer May 23
TELA Bio, Inc. Provides Revenue Guidance for the Year 2024 May 11
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023) May 10
TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
TELA Bio, Inc., Annual General Meeting, Jun 04, 2024 Apr 20
TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR Apr 17
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts Mar 24 TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX
Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022) Mar 23
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA) Mar 08
TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 01
Consensus EPS estimates fall by 215% Nov 16 TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 15
Price target decreased by 18% to US$14.40 Nov 12
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10
TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry? Oct 07
John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc Sep 29
TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery Aug 17
Consensus EPS estimates upgraded to US$0.57 loss Aug 17
Second quarter 2023 earnings: EPS exceeds analyst expectations Aug 10
TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023 Aug 10
Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult Jul 31
TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 13
Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023 May 12
Insufficient new directors May 01
Consensus EPS estimates fall by 13%, revenue upgraded Mar 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 23
TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack Jan 10
Price target decreased to US$17.40 Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 12
Price target decreased to US$17.40 Nov 11
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022 Nov 10
TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 28
TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair Oct 27
TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption Oct 02
Consensus forecasts updated Aug 18 TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million. Aug 16
Tela Bio prices $32M common stock offering Aug 16
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 11
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 11
Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs Aug 05
TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 28
CFO & COO recently bought US$83k worth of stock Jun 09
TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 24
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly? May 12
TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022 May 12
TELA Bio, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel Apr 19
TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution Mar 05
TELA Bio - Follow Up With Management Jan 14
High number of new directors Dec 31
Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020) Nov 12
Our First Look At TELA Bio Nov 04
TELA Bio Plugging Away Oct 25
TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique Sep 15
Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020) Aug 12
TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021 Aug 12
High number of new directors Aug 01 TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index
Independent Director Adele Oliva has left the company Jun 09
Chief Financial Officer Nora Brennan has left the company Jun 05
TELA Bio (TELA) Investor Presentation - Slideshow May 26
TELA Bio, Inc. Initiates Bravo II Study of Ovitex for the Robotic Repair of Ventral Hernias May 20
TELA Bio, Inc. Provides Revenue Guidance for the Full Year of 2021 May 16
CEO報酬分析 TELA Bio の収益と比較して、Antony Koblish の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a -US$42m
Jun 30 2024 n/a n/a -US$42m
Mar 31 2024 n/a n/a -US$40m
Dec 31 2023 US$2m US$595k -US$47m
Sep 30 2023 n/a n/a -US$44m
Jun 30 2023 n/a n/a -US$44m
Mar 31 2023 n/a n/a -US$45m
Dec 31 2022 US$2m US$566k -US$44m
Sep 30 2022 n/a n/a -US$43m
Jun 30 2022 n/a n/a -US$40m
Mar 31 2022 n/a n/a -US$36m
Dec 31 2021 US$2m US$538k -US$33m
Sep 30 2021 n/a n/a -US$32m
Jun 30 2021 n/a n/a -US$32m
Mar 31 2021 n/a n/a -US$30m
Dec 31 2020 US$806k US$479k -US$29m
Sep 30 2020 n/a n/a -US$28m
Jun 30 2020 n/a n/a -US$27m
Mar 31 2020 n/a n/a -US$29m
Dec 31 2019 US$2m US$403k -US$30m
Sep 30 2019 n/a n/a -US$32m
Jun 30 2019 n/a n/a -US$30m
Mar 31 2019 n/a n/a -US$28m
Dec 31 2018 US$569k US$375k -US$30m
報酬と市場: Antonyの 総報酬 ($USD 2.37M ) は、 US市場 ($USD 648.89K ) の同規模の企業の平均を上回っています。
報酬と収益: Antonyの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者 Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20 ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Co-founder 12.6yrs US$2.37m 1.22% $ 888.5k CFO & COO 3.2yrs US$1.06m 0.43% $ 309.2k Chief Technology Officer no data US$962.24k 0.21% $ 153.2k VP, Corporate Controller 3.5yrs データなし 0.033% $ 23.9k General Counsel & Corporate Secretary 2.6yrs データなし データなし Senior Vice President of Human Resources 2.8yrs データなし データなし Chief Commercial Officer no data データなし 0.23% $ 168.4k Senior Vice President of Technical Operations 2.8yrs データなし データなし Chief Commercial Officer 4.8yrs US$936.76k 0.055% $ 39.9k Investor Relations Contact Officer no data データなし データなし
もっと見る
経験豊富な経営陣: TELAの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 Co-founder 12.6yrs US$2.37m 1.22% $ 888.5k Independent Director 11.9yrs US$128.59k 0.045% $ 32.7k Independent Director 5yrs US$133.59k 0.025% $ 18.4k Independent Chairman of the Board 4.6yrs US$161.09k 0.025% $ 18.4k Independent Director 4.6yrs US$133.59k 0.025% $ 18.4k Independent Director 6yrs US$121.09k 0.025% $ 18.4k Director less than a year データなし データなし
もっと見る
経験豊富なボード: TELAの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
